Navidea, PETNet ink manufacturing deal
Article Thumbnail ImageAugust 21, 2013 -- Radiopharmaceutical developer Navidea Biopharmaceuticals and PETNet Solutions have signed a radiopharmaceutical manufacturing agreement.

To get access to this article and all of the content on AuntMinnie.com, create a free account or sign-in now.

Member Sign In:
  MemberID or E-mail Address:
  Password:
(?)

New AuntMinnie.com Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • The deal covers Navidea's fluorine-18-labeled NAV4694 product, an investigational beta-amyloid PET imaging agent, Navidea said. Under the terms of the agreement, PETNet Solutions will manufacture NAV4694 clinical trial material at select U.S. radiopharmacies, with the possibility of expanding into additional PETNet locations next year, according to the firm.

    NAV4694 is currently in phase II and III clinical trials in subjects who have signs or symptoms of cognitive impairment such as Alzheimer's disease, Navidea said.


    || About || Advertising || AuntMinnieCME.com || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 AuntMinnie.com. All Rights Reserved.